(Reuters) - U.S. health reviewers’ main concern with Eli Lilly & Co’s imaging agent for Alzheimer’s tests is whether technicians can properly read the scans and how useful they are in assessing the degenerative disease.
(Reuters) - U.S. health reviewers’ main concern with Eli Lilly & Co’s imaging agent for Alzheimer’s tests is whether technicians can properly read the scans and how useful they are in assessing the degenerative disease.
